What question did this study set out to answer?

This research aims to investigate how targeting the FGF1/FGFR pathway can improve the effectiveness of oxaliplatin and reduce peripheral neuropathy symptoms.

February 14, 2026Open Access

Targeting the FGF1/FGFR signaling pathway enhances the antitumor effect of oxaliplatin and alleviates chemotherapy-induced peripheral neuropathy

Key Points

This research aims to investigate how targeting the FGF1/FGFR pathway can improve the effectiveness of oxaliplatin and reduce peripheral neuropathy symptoms.
Examined the role of FGF1 in tumor progression and chemotherapy effectiveness.
Evaluated the impact of FGFR inhibitors on oxaliplatin efficacy.
Analyzed symptoms of chemotherapy-induced peripheral neuropathy in treated models.
Combining FGFR inhibitors with oxaliplatin significantly enhances its antitumor effect.
FGFR inhibitors decrease the symptoms related to oxaliplatin-induced peripheral neuropathy.

Abstract

FGF1 promotes tumor progression and impairs oxaliplatin's therapeutic efficacy by activating the FGFR signaling pathway, while also inducing neuropathic injury. Notably, combining oxaliplatin with FGFR inhibitors enhances antitumor efficacy and alleviates oxaliplatin-induced peripheral neuropathy (OIPN) symptoms.

Read Full Paperexternally

Bookmark

View Full Paper

Cite This Study

Xie et al. (Sun,) studied this question.

synapsesocial.com/papers/699010942ccff479cfe56d70 https://doi.org/https://doi.org/10.1016/j.jare.2026.02.005

Bookmark

View Full Paper